Dyadic International, Inc. vs. Kymera Therapeutics, Inc. Common Stock
DYAI
Dyadic International, Inc.
$0.78 +0.65%
VS KYMRKymera Therapeutics, Inc. Common Stock
$117.39 +2.60%
Dyadic International, Inc. and Kymera Therapeutics, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| DYAI | KYMR | |
|---|---|---|
| Market Cap | $32.07 million | $9.48 billion |
| Revenue (TTM) | — | $105.00 million |
| Net Income (TTM) | — | $-299,601,000 |
KYMR leads on 1 of 1 size & scale factors.
Valuation
| DYAI | KYMR | |
|---|---|---|
| Price / Book | — | 6.28 |
| Price / Sales | — | 90.30 |
DYAI and KYMR split the valuation factors evenly.
Profitability
| DYAI | KYMR | |
|---|---|---|
| Net Margin | — | -285.34% |
| Return on Equity | — | -19.85% |
DYAI and KYMR split the profitability factors evenly.
Risk & Sentiment
| DYAI | KYMR | |
|---|---|---|
| Short Interest | 0.01% | 0.24% |
DYAI leads on 1 of 1 risk & sentiment factors.
Dig deeper: DYAI overview, DYAI financials, KYMR overview, KYMR financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.